<DOC>
	<DOCNO>NCT00008489</DOCNO>
	<brief_summary>The purpose study compare gastrointestinal ( stomach intestine ) side effect 2 form Videx HIV-infected patient . Videx effective anti-HIV treatment many patient take medication due side effect . Videx EC capsule form drug may fewer side effect . Also , patient would take many pill since patient take Videx EC would take 1 capsule per day instead 2 tablet per day . This study see patient take Videx EC few side effect .</brief_summary>
	<brief_title>Comparing Side Effects Two Forms Videx HIV-Infected Adults</brief_title>
	<detailed_description>Despite therapeutic advantage proven efficacy treatment HIV-infected patient , didanosine may continue underutilized many patient experience undesirable gastrointestinal ( GI ) side effect palatability problem . Once-daily dose Videx EC expect improve patient adherence possible improve palatability remove GI side effect associate buffer include tablet . Videx EC once-daily dosing would improve pill burden decrease 2 tablet 1 capsule per day . Therefore , Videx EC may represent significant step toward achieve well patient satisfaction , improve regimen adherence , optimal virologic outcome Videx-containing regimen . Patients randomize either continue current Videx tablet-containing regimen additional 2 week replace Videx tablet Videx EC . Patients remain Videx tablet switch EC formulation Study Week 2 remain 4 week study period . For patient continue successfully complete Week 6 study visit , optional extend dosing period offer Videx EC become commercially available study funder terminates study . Blood specimens safety evaluation viral load collect Weeks 0 , 1 , 2 , 4 , 6 . For patient participate extended dosing period , visit schedule every 8 week . Symptom score 2 treatment group compare , primary comparison occur Week 2 visit . Analyses include change GSRS score administer clinician interview study visit . Assessment GI symptom , palatability feature , dose convenience , lifestyle effect , Videx preference evaluate patient . Adverse event assess objectively observation investigator patient .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>Didanosine</mesh_term>
	<criteria>Inclusion Criteria Patients may eligible study : Are HIVpositive . Are least 16 year old ( consent parent guardian require 18 ) . Are take stable Videxcontaining antiHIV regimen , use Videx tablet either twice day , least 2 week prior screen visit . Score 2 high GSRS questionnaire 1 follow symptom first 2 study visit : abdominal pain , nausea vomiting , borborygmus , abdominal distension , loose stool . Agree use effective barrier method birth control study . Are available least 8 week . Exclusion Criteria Patients eligible study : Are pregnant breastfeeding . Are take Videx liquid form , nelfinavir , amprenavir . Have history pancreatitis gallstone . Abuse alcohol require drug , opinion investigator , may increase risk pancreatitis . Have treatment active opportunistic ( AIDSrelated ) infection within 4 week screen visit . Patients chronic candidiasis ( yeast infection ) bacterial infection allow . Are receive plan receive chemotherapy cancer . Plan change medication within 8 week follow screen visit . Are receive investigational drug participate clinical trial involve antiHIV medication . Patients Phase IV study ( study evaluate longterm safety effectiveness drug , usually drug approve FDA ) may eligible . Have active , ongoing gastrointestinal disease infection colitis , diverticulitis , Crohn 's disease , peptic ulcer disease , giardiasis , cryptosporidiosis . Are unable take medication mouth . Have severe diarrhea . Have peripheral neuropathy ( condition affect nervous system ) condition prior therapy , opinion investigator , would affect study .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2002</verification_date>
	<keyword>Didanosine</keyword>
	<keyword>Gastrointestinal System</keyword>
	<keyword>Tablets</keyword>
	<keyword>Reverse Transcriptase Inhibitors</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Capsules</keyword>
</DOC>